Who We Are

DigiNeos Health is an innovative startup developing evidence-based digital medical devices for patients, aimed at improving and transforming healthcare through advanced technology.

Here’s a striking fact: on average, people living with a chronic disease receive only 2 hours of direct medical care per year 1.

For the remaining 8,758 hours, they are left to manage their health entirely on their own. This is where we want to make a difference.

1 World Health Organization

What Drives Us

A solid network

Experience and passion drive everything we do

A Team with Proven Experience

Behind DigiNeos is a team of professionals who have devoted years to clinical research, medical education, and digital health technologies.
We bring a strong foundation of expertise, putting our knowledge at the service of healthcare innovation.

Excellence-Driven Advisors

We are guided by a high-level Advisory Board composed of experts spanning regulatory affairs, legal matters, intellectual property, health psychology, and market access. A group of professionals who believe in our vision and actively support our mission.

A Network That Works

We don’t work in isolation. We actively collaborate with leading research centers, specialized software companies, and patient advocacy organizations. This collaborative network is our strength, enabling us to build solutions that truly work.

Centers of Excellence

We collaborate with leading clinical centers to ensure that the solutions we develop are grounded in strong clinical and scientific evidence, as well as in everyday clinical practice and direct patient care. This approach allows us to design technologies that truly respect patients’ needs and real-world experiences.

Our founders

Stefania Frasson

Stefania Frasson

Co-founder, CEO, Board member

Gualberto Gussoni

Co-founder, President, Board member

Eleonora Sfreddo Gallotta

Eleonora Sfreddo Gallotta

Co-founder, Board member

Paolo Primiero

Paolo Primiero

Co-founder
Sergio Scaccabarozzi

Sergio Scaccabarozzi

Co-founder

Erminio Bonizzoni

Co-founder
Mariangela Fumarola

Mariangela Fumarola

Co-founder
Luca Frasson

Luca Frasson

Intellectual Property

Alice Ravizza

Regulatory

Silvia Stefanelli

Silvia Stefanelli

Legal & Privacy

Nicola Merlin

Patient Representative

Pietro Derrico

Pietro Derrico

Health Technology Assessment

Antonello Gavazzi

Antonello Gavazzi

Medical Advisor

Michele Senni

Michele Senni

Scientific Coordinator Cardiologia

Francesco Biroli

Medical Advisor

Our Pipeline

We are committed to finding solutions for conditions with significant unmet patient needs and high clinical and social impact.
Improving patients’ lives is our priority.

Chronic Heart Failure

NeosHeart

A silent emergency that demands continuous care and personalized monitoring

gastrointestinal tract pathologies

Conditions with substantial clinical and social impact on patients’ lives

musculoskeletal system pathologies

Dysfunctional conditions with significant impact on daily quality of life

From episodic care to continuous support

We develop technology that provides patients with ongoing support, real-time insights, and personalized guidance grounded in clinical evidence.

What this means in practice

Our digital health solutions will deliver comprehensive support beyond the clinic by:

The value of standard care is enhanced by extending it into everyday life, empowering patients to better understand their condition, adhere to therapy, and recognize early warning signs.

heart monitoring app mockup

Let's Build the Future of Digital Therapeutics Together

We believe every patient deserves the best.

If you share our vision and want to learn more about how we are revolutionizing the world of digital therapeutics, let’s talk.

Cos’è una terapia digitale?

Una terapia digitale è una applicazione che può essere disponibile su un telefonino o su un tablet o su un PC che ha l’obiettivo di migliorare le condizioni di salute di pazienti affetti da malattie croniche. 

Le terapie digitali si differenziano dalle migliaia di app per il benessere disponibili negli store Internet, perchè sono dispositivi medici certificati sottoposti a rigorose sperimentazioni che ne documentano efficacia e sicurezza.

Le terapie digitali generalmente funzionano attraverso:

  • moduli di educazione-informazione del paziente basati sulle linee guida medico-scientifiche, per una migliore autogestione della malattia
  • reminder per la corretta assunzione di eventuali altre terapie e/o per i controlli clinici necessari
  •  raccolta di informazioni sulla salute del paziente (sintomatologia – parametri vitali – esami di laboratorio etc.)
  • integrazione in tempo reale delle informazioni sulla salute del paziente ed elaborazione (attraverso algoritmi supportati dall’intelligenza artificiale) di raccomandazioni comportamentali (esempio adeguamento di altre terapie – esecuzione di controlli clinici – consiglio di rivolgersi tempestivamente al medico curante etc.)

 

In sintesi, una terapia digitale NON si sostituisce al Medico, ma affianca quotidianamente il paziente guidandolo verso una gestione più efficace della sua malattia.

What is a digital therapeutic?

A digital therapeutic is a smartphone, tablet, or computer application designed to improve health outcomes for patients with chronic conditions.

Unlike the thousands of wellness apps available in app stores, digital therapeutics are certified medical devices that undergo rigorous clinical trials demonstrating their efficacy and safety.

Digital therapeutics typically work through:

  • Evidence-based patient education modules grounded in clinical guidelines to enhance disease self-management
  • Intelligent reminders for medication adherence and clinical appointments
  • Continuous collection of patient health data (symptoms, vital signs, lab results, etc.)
  • Real-time integration and AI-powered analysis of health data to generate actionable recommendations (such as therapy adjustments, clinical check-ups, or prompts to contact healthcare providers)

 

In essence, a digital therapeutic does NOT replace your physician—it’s a daily companion that guides you toward more effective management of your condition.

Stefania Frasson holds a degree in Pharmaceutical Chemistry and Technology from the University of Milan.

She has over ten years of experience as a Project Manager at the Research Center of a Scientific Society, where she managed numerous national and international multicenter clinical research projects. These projects led to publications in leading scientific journals, including The New England Journal of Medicine, Blood, and the European Journal of Internal Medicine.

Throughout her career, she has been involved in all key phases of clinical trial design and execution, including protocol development, site selection and regulatory approvals, project management, pharmacovigilance, and the preparation of final study reports and manuscripts for publication.

Stefania has participated as a speaker at national and international conferences, presenting research outcomes from the projects she managed as well as topics related to research methodology. She has also contributed to the design and delivery of educational programs for healthcare professionals, particularly physicians and nurses.

In addition, she has worked on cross-cutting initiatives aimed at promoting clinical research in Italy, collaborating on editorial projects focused on non-profit research, public–private partnerships, and digital therapeutics.

During the 2022–2023 academic year, she served as a tutor for an online second-level Master’s program in Clinical Research promoted by UnitelmaSapienza University.

She is the author of numerous scientific articles published in national and international journals.

Gualberto Gussoni is a physician specialized in Pharmacology, with a clinical background in hospital settings (Internal Medicine and Infectious Diseases) as well as experience as a General Practitioner.

He also brings nearly 15 years of experience as a clinical researcher in both Italian and multinational pharmaceutical companies.

From 2007 to 2023, he served as Scientific Director and Coordinator of the Italian Society of Internal Medicine (FADOI), where he led clinical research activities (over 50 completed studies) and educational programs.

A former adjunct professor at the University of Pavia, he has taught in specialist and postgraduate training programs at several Italian universities, including Florence, Pisa, Rome (Sapienza, LUISS, Unimarconi), Catania, Padua, Bologna, Siena, and LIUC–Castellanza, with a focus on clinical research methodology.
In the 2022–2023 academic year, he served as Director of a second-level online Master’s program in Clinical Research run by UnitelmaSapienza University.

He is the author of more than 90 articles published in national and international journals (H-index ≈ 20) and has received international recognition for original clinical research in the fields of cardiovascular, endocrine, and infectious diseases.

He has promoted and led studies that contributed to changes in international clinical guidelines for cardiovascular conditions, including venous thromboembolic complications in cancer patients and acute limb ischemia.

His publications also include nationally and internationally relevant volumes on digital therapeutics, decentralized clinical trials, non-profit research, and public–private collaboration in clinical research.

An official reviewer and Editorial Board member of leading specialty journals in Internal Medicine, Hemostasis and Thrombosis, and Pharmacology, he has served as a speaker or chair at more than 150 national and international conferences.

Since June 2019, he has been a member of the Healthcare Professionals Working Party of the European Medicines Agency (EMA), representing the European Federation of Internal Medicine (EFIM).

Eleonora Sfreddo Gallotta is a senior professional with over 35 years of experience in clinical research, biostatistics, and the management of ethics committees within the healthcare sector.

Since September 2014, she has served as Chief Operating Officer at FROM – Fondazione Ricerca Ospedale di Bergamo (ETS), where she coordinates the foundation’s activities dedicated to medical research and the management of innovative scientific projects, including the Italian Angelman Syndrome Registry.

Her career has evolved through roles of increasing responsibility in ethics committee management and clinical research. From 2013 to 2017, she served as Head of the Technical and Scientific Secretariat of the Milan Area C Ethics Committee at Niguarda Hospital, a role she had previously held from 2010 to 2013. In these positions, she was responsible for coordinating and reviewing clinical trial documentation, managing the AIFA National Clinical Trials Observatory, and liaising with institutional bodies, study start-up units, and local investigators.

She also served as a member of several Ethics Committees at hospitals in Milan and Lombardy (including Fatebenefratelli Hospital and Melegnano Hospital) from 2006 to 2012, contributing her expertise in biostatistics and clinical research.

For nearly 18 years (1996–2014), she worked as a consultant for pharmaceutical companies and Contract Research Organizations (CROs), focusing on data entry, data management, statistical analysis of clinical studies, and support for study start-up activities.

She began her career in 1986 at Nino Bergamini & Associates, where she became Head of Data Management and Statistical Analysis in 1991, overseeing clinical trial databases and coordinating data entry activities until 1996.

Her expertise spans biostatistics, clinical trial management, ethical and regulatory frameworks, and the coordination of research projects in rare diseases, positioning her as a leading reference figure in the Italian clinical research landscape.

Paolo Primiero holds a degree in Medicine and Surgery from Sapienza University of Rome, with certification to practice as a General Practitioner.

He has worked in clinical research since 1990, initially as a consultant for monitoring and managing project activities as an independent professional and, starting in 2003, as proposer and academic coordinator of several Level II Master’s programs on clinical trials at Sapienza University of Rome and Tor Vergata University of Rome, as well as author of the curriculum for clinical research courses first in Pharmacy and then in the Master’s in Clinical Research – Master’s Degree in Biotechnology (Tor Vergata University of Rome).

He served as head of a working group at UNI (Italian National Standards Body) and was the principal author of the document “Voluntary Self-Regulation Standards for Clinical Monitors.”

From 2017 to 2022 and from 2022 to 2023, Paolo served as President and Chief Executive Officer, respectively, of FoRT (Foundation for Translational Research – oncology area).

He currently serves as President of Assomonitor (the Italian Association representing Clinical Monitors/Clinical Research Associates) and as Adjunct Professor in “Fundamentals of Clinical Research” for the Biotechnology degree program at Tor Vergata University of Rome.

Sergio Scaccabarozzi holds a medical degree and specialization in general surgery from the University of Milan, and brings 35 years of experience in clinical research for global pharmaceutical and biotechnology companies.

Throughout his professional career, Sergio spent 12 years as head of clinical operations for the Italian affiliate of a major pharmaceutical and biotechnology company, managing a team of over 90 people and more than 220 studies spanning Phase I through Phase IV, real-world evidence (RWE), and providing support to institutions for investigator-initiated studies.

Sergio further enriched his professional experience by serving for a year and a half as Operation Research Manager at one of Italy’s leading public research hospitals.
Since February 2023, he has served as Scientific Director (part-time) at Arithmos, a company dedicated to transforming the life sciences industry through technological solutions, quality compliance, and consulting services.

Sergio is a member of scientific societies and working groups on Clinical Research, a recognized speaker at national and international events, and maintains an active editorial presence on Clinical Research and Life Sciences more broadly.

Erminio Bonizzoni holds a degree in Biology from the University of Pavia and a specialization in Medical Statistics from the Institute of Medical Statistics and Biometry at the University of Milan.

He taught at the same specialization school for over 10 years as an adjunct professor and served as a statistical reviewer for several international medical journals, including The Lancet.

Erminio worked for more than 25 years as a consultant in Medical Statistics for drug development and regulatory affairs at national and international pharmaceutical companies.

Throughout his consulting career, he has worked across all phases (I through III) of drug development, as well as in post-marketing studies (Phase IV), has had interactions with the FDA and EMA, and has served on Data Safety Monitoring Boards as a statistics expert.

He has published over 120 scientific articles in international journals.

Mariangela Fumarola is a seasoned professional with over 18 years of experience in clinical research and operational management, with particular expertise in Phase I studies and Good Clinical Practice.
Since May 2023, she has served as Clinical Operations Manager at FROM Foundation for Research at Bergamo Hospital (ETS), where she coordinates clinical operations while applying her skills in leadership, contract negotiation, quality management, and strategic planning.

Her career trajectory reflects progressively senior roles: she spent over five years as Grant Officer at the Foundation for Research at Bergamo Hospital (2017-2022), worked in the Secretariat of the Ethics Committee Milan Area C at Niguarda Ca’ Granda Hospital (2013-2016), and began her career providing administrative and management support for clinical studies at San Gerardo Hospital in Monza (2006-2013).

She also contributed to launching the Phase 1 Unit at ASST San Gerardo in Monza, where she was responsible for drafting standard operating procedures in compliance with AIFA (Italian Medicines Agency) regulations.
Her expertise spans operational management, contract negotiation, budget development, and team leadership, supported by comprehensive knowledge of Good Clinical Practice regulations and quality systems in biomedical research.

DigiNeos marchio

Want to learn more about DigiNeos Health?

Fill out the form and we’ll send you a project prospect outlining our vision, scientific approach, and upcoming development milestones.